MEDNAX (NYSE:MD) has been given a $62.00 price target by investment analysts at Stephens in a research report issued on Thursday. The brokerage presently has a “buy” rating on the stock. Stephens’ target price indicates a potential upside of 14.94% from the stock’s previous close.
MD has been the subject of a number of other reports. Jefferies Group set a $50.00 price target on shares of MEDNAX and gave the company a “hold” rating in a report on Tuesday. Mizuho set a $49.00 price target on shares of MEDNAX and gave the company a “hold” rating in a report on Wednesday, January 24th. Stifel Nicolaus reaffirmed a “hold” rating and set a $56.00 price target on shares of MEDNAX in a report on Wednesday, January 24th. Zacks Investment Research raised shares of MEDNAX from a “hold” rating to a “buy” rating and set a $60.00 price target for the company in a report on Tuesday, January 23rd. Finally, Citigroup lowered their price target on shares of MEDNAX from $52.00 to $47.00 and set a “neutral” rating for the company in a report on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $55.08.
MEDNAX (NYSE MD) opened at $53.94 on Thursday. MEDNAX has a one year low of $40.56 and a one year high of $72.13. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.62. The company has a market cap of $4,920.00, a price-to-earnings ratio of 15.68, a PEG ratio of 1.40 and a beta of 0.31.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total transaction of $154,740.00. Following the completion of the transaction, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,834,649.02. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.40% of the stock is owned by company insiders.
Hedge funds have recently made changes to their positions in the business. Prudential Financial Inc. grew its holdings in MEDNAX by 976.9% during the 3rd quarter. Prudential Financial Inc. now owns 641,057 shares of the company’s stock worth $27,642,000 after acquiring an additional 581,527 shares in the last quarter. Quantbot Technologies LP acquired a new position in MEDNAX during the 3rd quarter worth $695,000. Nomura Holdings Inc. acquired a new position in MEDNAX during the 2nd quarter worth $347,000. Point72 Asset Management L.P. grew its holdings in MEDNAX by 71.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 132,700 shares of the company’s stock worth $5,722,000 after acquiring an additional 55,400 shares in the last quarter. Finally, Advisor Group Inc. grew its holdings in MEDNAX by 41.9% during the 3rd quarter. Advisor Group Inc. now owns 8,361 shares of the company’s stock worth $359,000 after acquiring an additional 2,468 shares in the last quarter. 98.67% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.com-unik.info/2018/02/10/mednax-md-given-a-62-00-price-target-at-stephens.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.